PRECISION BIOSCIENCES, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 109
- Market Cap
- -
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients with Chronic Hepatitis B
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06680232
- Locations
- 🇲🇩
ICS ARENSIA Exploratory Medicine SRL, Chisinau, Moldova, Republic of
A Long-term Follow-up Study of Participants Who Received an Allogeneic CAR T-Cell Product
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05822427
- Locations
- 🇺🇸
Science 37, Inc., Culver City, California, United States
Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT04649112
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸Lifespan Cancer Institute at Rhode Island Hospital, Providence, Rhode Island, United States
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04171843
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Precision BioSciences, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04030195
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
© Copyright 2024. All Rights Reserved by MedPath